At present, AFP is used as a serum biomarker to assist in the diagnosis or screening of high-risk liver cancer patients (42), but approximately 30–40% of overall hepatocellular carcinoma patients have very low serum AFP levels (<20 ng/ml), which is called AFP-negative HCC (43). The gene discussed is AFP; the disease is liver cancer.